CION Ameerpet
Clear cell is not the ovarian cancer that most of what you will read online is about. It is uncommon, it usually grows out of endometriosis rather than the fallopian tube, and it is more often found early — which is genuinely good news. It also responds less predictably to standard chemotherapy once it has spread, and you deserve to hear that plainly rather than discover it later.
The name is a description of what a pathologist sees, nothing more sinister than that. In clear cell ovarian carcinoma the cells are packed with glycogen, which washes out during laboratory processing and leaves the cytoplasm looking empty — clear — under the microscope. The word says nothing about how the cancer will behave. What follows on this page does.
It is uncommon. Clear cell accounts for a small share of epithelial ovarian cancers in Western series, and a noticeably larger share in East Asian populations. Most of the survival figures, treatment descriptions and forum threads you will find when you search ovarian cancer are describing high-grade serous carcinoma, which is a genuinely different disease. Reading those numbers as though they applied to you is the single commonest mistake made after this diagnosis.
Two things separate clear cell from the commonest subtype, and both matter practically. It usually grows out of endometriosis rather than the fallopian tube, which is why it appears earlier in life and often as a single large cyst rather than as disease scattered across the abdomen. And once it has spread, it responds less predictably to platinum-based chemotherapy than serous cancers do. The first fact is in your favour. The second is why complete surgery carries so much weight here.
Glycogen inside the cells washes out during processing, leaving them looking clear. It is not a statement about severity.
A small share of ovarian cancers overall, and a larger share in East Asian populations than in Western series.
Different origin, different molecular changes, different behaviour. Serous statistics do not transfer to it.
Clear cell carcinoma is one of the few cancers whose starting point can be seen under a microscope. In 2010, Wiegand and colleagues sequenced ovarian clear cell and endometrioid carcinomas and found mutations in ARID1A — a gene that helps keep DNA correctly packaged — in around half of the clear cell tumours. The same mutation was present in the atypical endometriosis lying immediately beside the tumour, but not in endometriosis further away. That is about as close as pathology gets to watching a benign lesion turn. It is also why endometriosis-associated ovarian cancer is now treated as its own biological story rather than a variant of the commoner serous type. Source: Wiegand KC et al., New England Journal of Medicine (2010); WHO Classification of Tumours, Female Genital Tumours, 5th edition.
This is the part women with endometriosis come here for, so let us take it in the right order — the reassurance first, then the honest detail.
The great majority of endometriosis never becomes cancer. Endometriosis is common, it affects women for decades, and the overwhelming majority of those women never develop an ovarian malignancy of any kind. If you have endometriosis and you are reading this at night, that is the sentence to hold on to.
The association is nonetheless real, and it is specific rather than general. Only two ovarian cancer subtypes arise from endometriosis: clear cell carcinoma and endometrioid carcinoma. Both usually begin in a long-standing ovarian endometrioma — the cyst often called a chocolate cyst — where repeated bleeding, iron and inflammation give the lining cells decades of opportunity to accumulate genetic damage. The detail of who is at higher risk, and why, is set out in our guide to endometriosis and ovarian cancer risk.
What this does not justify is surveillance for its own sake. There is no screening test that reliably picks up clear cell carcinoma early, and repeat CA-125 testing in a woman with endometriosis mostly generates alarm — endometriosis itself raises CA-125. What is worth attention is change: an endometrioma that is enlarging, one that develops a solid nodule with blood flow in its wall, one that behaves differently on MRI, or any endometrioma that persists or appears after the menopause. Those are the findings that earn a specialist opinion.
Endometriosis is common and ovarian cancer is not. The overwhelming majority of endometriosis never becomes malignant, and the absolute risk to any one woman stays low across a lifetime. Pain, however severe, is not itself a cancer signal — endometriosis causes plenty of pain without causing cancer.
Change in a known endometrioma rather than its presence: growth, a solid nodule with blood flow inside the cyst wall, an altered appearance on MRI, or a cyst that persists or first appears after the menopause. New, constant pelvic pain in a woman whose endometriosis had settled belongs in the same list.
Endometriosis raising CA-125 is precisely why a CA-125 taken in isolation is such an unhelpful test here. It is read alongside imaging, your age and menopausal status, or it is not read at all.
Almost everything published about ovarian cancer describes high-grade serous carcinoma. Here is where your diagnosis parts company with it, and what each difference means in practice.
| Feature | Clear cell carcinoma | High-grade serous (the commonest type) |
|---|---|---|
| Where it starts | Usually within endometriosis, most often a long-standing ovarian endometrioma. | Usually the fimbrial end of the fallopian tube, not the ovary itself. |
| Typical age at diagnosis | Often the forties and fifties — younger than the ovarian cancer average. | More often after 60. |
| Stage when found | More often stage I, as a large one-sided pelvic mass. | Usually advanced, already spread across the peritoneal surfaces. |
| CA-125 | Less reliably raised. A normal or modest level does not exclude it. | Usually raised, and genuinely useful for monitoring response. |
| Molecular signature | ARID1A and PIK3CA alterations are common; TP53 usually intact. | TP53 mutation in almost all cases; roughly half show HRD. |
| Response to platinum chemotherapy | Less predictable, particularly once disease has spread. | Typically sensitive, and response is often substantial. |
| What most influences outcome | Stage at diagnosis and whether every visible deposit was removed. | Complete cytoreduction and continued platinum sensitivity. |
*The overlap with endometrioid carcinoma is real: the two share an origin in endometriosis and some of the same molecular changes, and occasionally both are present in the same ovary. How each is treated in Hyderabad is set out on our ovarian cancer treatment page.
These come up constantly with this subtype and are frequently not covered unless you raise them. None is a difficult question to ask.
Ask which sites were sampled — washings, omentum, nodes, peritoneal biopsies. In an early clear cell cancer, complete staging is what the plan rests on.
Your pathology report usually says. It supports the diagnosis and explains why this happened, which many women want to know.
Clear cell is one of the subtypes seen in Lynch syndrome. The result affects your relatives and can affect later treatment options.
Less often positive here than in serous cancer, but the result still guides what maintenance treatment can be considered. Both are in-house at CION.
In stage IA the case for adjuvant chemotherapy is genuinely debated. Ask for the reasoning behind your recommendation rather than assuming it is automatic.
Clear cell carries a higher rate of venous thrombosis than other ovarian subtypes. Ask what to watch for and whether prevention is warranted.
On that last point: new swelling or pain in one leg, or sudden breathlessness or chest pain, is a same-day call to your treating team — not something to wait out. It is a recognised association with this subtype, and it is treatable when caught quickly.
Clear cell is managed differently from the commonest ovarian cancer in ways that matter — how completely it was staged, whether adjuvant treatment is needed, and which tests are worth doing. Bring your pathology report and we will go through it line by line.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy, genetic counselling and BRCA, HRD and mismatch repair testing are all delivered in-house at CION.
The framework is the same as for other epithelial ovarian cancers — surgery and chemotherapy — but the weight given to each part shifts with this subtype.
Because clear cell is more often confined to one ovary when it is found, surgery does more of the work here than in any other subtype. The operation removes the tumour and stages the abdomen properly: washings for cells, the omentum, lymph nodes and peritoneal biopsies. Understaging is the real danger — a cancer called stage I on an incomplete operation may not be stage I at all.
Outcomes are better when this is performed by a specialist gynaecologic-oncology surgeon. At CION, staging and debulking surgery is coordinated with specialist partner centres and may be billed there. We would rather say that plainly at the start than have you find out at the billing counter.
Platinum-based chemotherapy remains the standard backbone, and it is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh. In early-stage disease that has been completely removed, it is given to deal with what cannot be seen, and the outlook after it is good.
In advanced or recurrent clear cell disease, response rates to platinum are lower than in serous cancer. That is a well-recognised property of the subtype rather than a failure of your treatment, and it is why an anti-angiogenic drug class is sometimes added, why clinical trial options are discussed earlier, and why a second opinion on the plan is entirely reasonable at this point.
A completely removed, completely staged stage I clear cell cancer sits at the favourable end of ovarian cancer outcomes, and this is worth hearing clearly because it is easily lost among the frightening things written about the subtype generally.
The debate in stage IA is whether chemotherapy adds anything after complete surgery; in stage IC, where the capsule ruptured or cancer cells were found in the washings, adjuvant chemotherapy is usual. Ask which of these describes you, since it changes the conversation entirely.
Three tests are worth asking about. Germline BRCA and tumour HRD testing, which are less often positive in clear cell than in serous cancer but still guide whether maintenance therapy applies. Mismatch repair or MSI testing, because clear cell is one of the ovarian subtypes associated with Lynch syndrome. And, in recurrent disease, whether the tumour profile opens an immune checkpoint inhibitor-class option or a trial.
Genetic counselling and BRCA, HRD and mismatch repair testing are delivered in-house at CION, alongside the treatment those results point towards — so the test, its interpretation and what follows from it stay with one team rather than being scattered across three.
Clear cell is diagnosed younger than most ovarian cancers, so this question arrives more often here than elsewhere. In carefully selected women with early, one-sided disease and complete staging, removing only the affected ovary and tube while preserving the uterus and the other ovary can be discussed.
It is a considered decision rather than a default, it depends on stage and on what the pathology shows, and the surgery itself is coordinated with specialist gynaecologic-oncology partner centres. Raise it before surgery is planned, not after — the options narrow considerably once the operation has happened.
Recurrent clear cell disease is managed on the same logic as other ovarian cancers, with one adjustment: because platinum sensitivity is less dependable in this subtype, non-platinum drug classes and clinical trials come into the conversation sooner. The interval since chemotherapy finished still guides the choice.
This is also the point where molecular results earn their keep. A tumour with mismatch repair deficiency, or one with a targetable pathway alteration, may open options that would never surface without testing. If no molecular testing has been done by the time of recurrence, ask for it.
Everyone diagnosed searches for survival figures, and there is no point pretending otherwise. The problem with the ones you will find for this subtype is not that they are hostile — it is that they are built to mislead anyone reading them as a personal forecast.
They are historical, describing women treated years ago under different staging practice and before molecular testing was routine. They average stage I and stage IV together, which is particularly distorting in clear cell because so much of the outcome is decided by stage and by whether every visible deposit was removed. They mix complete and incomplete surgery in a subtype where that difference is decisive. And because clear cell is uncommon, many published series are small, so the numbers move around between studies in ways that reflect sample size rather than biology.
CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. Those are one-year figures across the whole treated ovarian population, not cure rates and not a prediction for any individual. Your own outlook is a conversation to have with your oncologist, who can speak to your stage, your surgery and your pathology rather than to an average.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure. *One-year survival; national registry data.
In clear cell, outcome turns heavily on stage at diagnosis and on whether surgery removed everything visible.
Pooled figures mix early and advanced disease, complete and incomplete surgery, and decades of changing practice.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals — discuss your own prognosis with your treating oncologist.
With an uncommon subtype, the risk is being managed as though it were the common one. The questions that decide a clear cell plan are specific: was the staging complete, did the tumour arise in endometriosis, is this stage IA or IC, has mismatch repair testing been done, and does adjuvant chemotherapy actually add anything in your case. Those need a proper appointment, not a five-minute review of a discharge summary.
Your first consultation at CION is free and runs to about 45 minutes. Bring the pathology report, the operation note if you have it, and any imaging. Every case that raises a question goes to a tumour board — medical oncology, imaging and pathology together — rather than being decided by one doctor alone.
Chemotherapy, maintenance therapy, genetic counselling and BRCA, HRD and mismatch repair testing are delivered in-house at CION, across more than 35 centres in Telangana and Andhra Pradesh, so treatment continues near where you live rather than requiring repeated travel while you are unwell. Staging, debulking and fertility-sparing surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — outcomes are better in specialist hands, which is why it is arranged that way, and we state it upfront. The full pathway is described on our ovarian cancer treatment in Hyderabad page, and the wider picture in our complete ovarian cancer guide.
Free, unhurried and with a specialist. Long enough to read your pathology report properly rather than skim it.
BRCA, HRD and mismatch repair testing, chemotherapy and maintenance therapy all delivered in-house at CION.
Multidisciplinary review before a plan is set — which matters more, not less, when the subtype is uncommon.
Staging and debulking at specialist gynaecologic-oncology partner centres, and may be billed there.
It is an uncommon subtype of epithelial ovarian cancer, named for how the cells look under the microscope: they are packed with glycogen, which washes out during laboratory processing and leaves the cytoplasm looking empty, or clear. The name describes appearance, not severity. What matters more is its biology. Clear cell usually arises within endometriosis, most often a long-standing ovarian endometrioma, rather than in the fallopian tube where the commonest ovarian cancer begins. It tends to be diagnosed younger, is more often confined to one ovary when found, and behaves differently from serous cancer in how it responds to chemotherapy.
No. Endometriosis is common, ovarian cancer is not, and the overwhelming majority of women with endometriosis never develop either. The association is real but specific: only two ovarian cancer subtypes arise from endometriosis, clear cell and endometrioid carcinoma, and both usually begin in a long-standing ovarian endometrioma. The absolute risk to any one woman remains low across a lifetime. Repeat CA-125 testing is not a useful safeguard, because endometriosis itself raises CA-125. What deserves a specialist look is change in a known endometrioma: growth, a solid nodule with blood flow in the cyst wall, an altered appearance on MRI, or a cyst appearing after the menopause.
That question mixes two different things. Clear cell is more often caught at an early stage than the serous subtypes, because it usually grows as a single sizeable cyst that causes symptoms rather than spreading silently across the abdomen. Early-stage disease that is completely removed and completely staged sits at the favourable end of ovarian cancer outcomes. Once it has spread beyond the pelvis, however, it responds less predictably to platinum-based chemotherapy than serous cancer does, which makes advanced clear cell harder to treat. So the honest answer is that stage matters more in this subtype than in almost any other.
Platinum-based chemotherapy remains the standard treatment and it is given for exactly the same reasons as in other ovarian cancers. In early-stage disease that has been completely removed, it is used to deal with what cannot be seen, and the outlook afterwards is good. In advanced or recurrent disease, response rates are lower than in serous cancer. That is a recognised property of the subtype rather than a failure of treatment or of your body. It is also why an anti-angiogenic drug class is sometimes added, why molecular testing is worth doing, and why clinical trial options are raised earlier here than in other subtypes.
Mostly on two things: the stage at diagnosis, and whether surgery removed every visible deposit with complete staging. Both weigh more heavily here than in other subtypes. The survival figures found online are hard to apply to an individual because they are historical, they average stage I and stage IV together, they mix complete and incomplete surgery, and the published series are often small since the subtype is uncommon. CION reports 81.0% one-year survival against a national figure of 73.7% across its treated ovarian population, but even that describes a group rather than a person. Ask your oncologist about your own stage and pathology.
Yes, testing is worth having, though the reasons differ slightly from the serous subtype. Clear cell is one of the ovarian cancers seen in Lynch syndrome, so mismatch repair or MSI testing on the tumour is important: it can point to an inherited condition that affects your relatives and your own bowel and endometrial screening, and it may open additional treatment options if the disease returns. Germline BRCA and tumour HRD testing are less often positive in clear cell than in serous cancer, but still guide whether maintenance therapy applies. Genetic counselling and all three tests are delivered in-house at CION.
The first consultation is free and runs to about 45 minutes — bring your pathology report, the operation note if you have one, and any imaging. Chemotherapy and maintenance therapy are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, as are genetic counselling and BRCA, HRD and mismatch repair testing. Staging, debulking and fertility-sparing surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there, because outcomes are better in specialist hands; we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board.